
MEDIA RELEASE

Ypsomed opens production plant in Schwerin, Germany

Burgdorf, 22.08.2019, 7.00 a.m. – Ypsomed opens its new production plant in Schwerin, in north-eastern Germany. Ypsomed is thus ensuring the necessary production capacities for growth in the coming years. Around 200 jobs will be created at the new production site over the next few years.

After a construction period of around two years, the ultra-modern production plant for medical technology has commenced operations and is now officially opened. In addition to Ypsomed's Board of Directors and Executive Management, the German Federal Health Minister Jens Spahn, the Prime Minister of Mecklenburg-Vorpommern Manuela Schwesig, Mecklenburg-Vorpommern's Economics Minister Harry Glawe and representatives of industry and commerce from the region will take part in the opening ceremony.

Capacity expansion for future growth

At the production site, Ypsomed will manufacture injection and infusion systems as well as infusion sets for insulin pumps. In addition to production, the new site will also include a logistics warehouse, quality control and technical maintenance. In addition, the new production plant is equipped with state-of-the-art clean rooms, plastic injection moulding machines, printing equipment and automatic assembly and packaging machines.

"In Schwerin, we have built a state-of-the-art production plant for medical technology. After the full expansion of our Swiss sites, the new production plant will provide us with the necessary capacity expansion to ensure our growth over the next few years. The location in north-eastern Germany offers ideal conditions for this, especially with regard to qualified employees," comments Simon Michel, CEO of Ypsomed, on the move to Schwerin.

Around 200 new jobs in the region

At least 150 jobs will be created in the region in a first phase, which could be increased to over 200 as production capacity utilisation increases.

Manuela Schwesig, Prime Minister of Mecklenburg-Vorpommern, welcomes Ypsomed's move to Schwerin: "The new Ypsomed production plant will create new high-quality jobs here in Mecklenburg-Vorpommern. I am delighted that our location advantages have convinced the Swiss company. The new site is proof of Mecklenburg-Vorpommern's attractiveness as a business location. It is also a result of the country's intensive advertising in Switzerland, which continues to be an interesting market for us".

Facts and figures about the new Ypsomed production site in Schwerin:

- 100,000 m² of land, option of an additional 2 x 50,000 m²
- 24,000 m² building area, 13,500 m² production area, 4,250 m² warehouse area
- 24 months construction time
- € 100 million investment costs for buildings, infrastructure and planned production facilities
- 150 jobs in the first five years with additional jobs and increasing production capacity utilisation

More information and pictures of the new production site in Schwerin as well as pictures of the opening ceremony (from 22.08.2019, 16:00 h) can be found at www.ypsomed.com/opening-schwerin.

For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG, at the telephone number +41 34 424 35 55 or by e-mail (thomas.kutt@ypsomed.com).

About the Ypsomed Group

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1 700 employees. Additional information is available under www.ypsomed.com.